Indo US Bio-Tech [INDOUS] vs UPL [UPLPP] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Indo US Bio-Tech Ltd. wins in 9 metrics, UPL Ltd. wins in 11 metrics, with 0 ties. UPL Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Indo US Bio-Tech Ltd. | UPL Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 14.45 | 3.00 | UPL Ltd. |
| Price-to-Book Ratio | 2.48 | 1.63 | UPL Ltd. |
| Debt-to-Equity Ratio | 31.90 | 105.06 | Indo US Bio-Tech Ltd. |
| PEG Ratio | -0.35 | -0.05 | UPL Ltd. |
| EV/EBITDA | 13.03 | 13.32 | Indo US Bio-Tech Ltd. |
| Profit Margin (TTM) | 12.59% | 0.09% | Indo US Bio-Tech Ltd. |
| Operating Margin (TTM) | 17.24% | 13.51% | Indo US Bio-Tech Ltd. |
| EBITDA Margin (TTM) | 17.24% | 13.51% | Indo US Bio-Tech Ltd. |
| Return on Equity | 20.72% | 2.01% | Indo US Bio-Tech Ltd. |
| Return on Assets (TTM) | 16.63% | 0.86% | Indo US Bio-Tech Ltd. |
| Free Cash Flow (TTM) | $5.57M | $84.56B | UPL Ltd. |
| Dividend Yield | 0.16% | 0.69% | UPL Ltd. |
| 1-Year Return | -41.80% | 104.96% | UPL Ltd. |
| Price-to-Sales Ratio (TTM) | 1.82 | 1.38 | UPL Ltd. |
| Enterprise Value | $2.42B | $724.61B | UPL Ltd. |
| EV/Revenue Ratio | 2.06 | 1.61 | UPL Ltd. |
| Gross Profit Margin (TTM) | 29.90% | 54.76% | UPL Ltd. |
| Revenue per Share (TTM) | $59 | $570 | UPL Ltd. |
| Earnings per Share (Diluted) | $7.40 | $-0.74 | Indo US Bio-Tech Ltd. |
| Beta (Stock Volatility) | -0.19 | 0.83 | Indo US Bio-Tech Ltd. |
Indo US Bio-Tech Ltd. vs UPL Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Indo US Bio-Tech Ltd. | 2.91% | -4.98% | -8.53% | -30.12% | -27.41% | -20.69% |
| UPL Ltd. | 0.00% | 0.00% | 0.00% | 16.46% | 24.26% | 24.26% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Indo US Bio-Tech Ltd. | -41.80% | -65.89% | -65.89% | -65.89% | -65.89% | -65.89% |
| UPL Ltd. | 104.96% | 104.96% | 104.96% | 104.96% | 104.96% | 104.96% |
Performance & Financial Health Analysis: Indo US Bio-Tech Ltd. vs UPL Ltd.
| Metric | INDOUS | UPLPP |
|---|---|---|
| Market Information | ||
| Market Cap | ₹2.11B | ₹620.31B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 22,336 | 1,096 |
| 90 Day Avg. Volume | 55,705 | 441 |
| Last Close | ₹98.35 | ₹516.50 |
| 52 Week Range | ₹94.82 - ₹206.00 | ₹216.20 - ₹563.85 |
| % from 52W High | -52.26% | -8.40% |
| All-Time High | ₹388.40 (Dec 09, 2024) | ₹563.85 (Jul 30, 2025) |
| % from All-Time High | -74.68% | -8.40% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.03% | 0.10% |
| Quarterly Earnings Growth | -0.41% | 0.02% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.00% |
| Operating Margin (TTM) | 0.17% | 0.14% |
| Return on Equity (TTM) | 0.21% | 0.02% |
| Debt to Equity (MRQ) | 31.90 | 105.06 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹43.18 | ₹318.92 |
| Cash per Share (MRQ) | ₹0.29 | ₹51.99 |
| Operating Cash Flow (TTM) | ₹34.25M | ₹70.93B |
| Levered Free Cash Flow (TTM) | ₹162.67M | ₹7.59B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.16% | 0.69% |
| Last 12-Month Dividend | ₹0.25 | ₹3.00 |
Valuation & Enterprise Metrics Analysis: Indo US Bio-Tech Ltd. vs UPL Ltd.
| Metric | INDOUS (Apr 24, 2026) | UPLPP (Sep 14, 2025) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 14.45 | 3.00 |
| Forward P/E | N/A | N/A |
| PEG Ratio | -0.35 | -0.05 |
| Price to Sales (TTM) | 1.82 | 1.38 |
| Price to Book (MRQ) | 2.48 | 1.63 |
| Market Capitalization | ||
| Market Capitalization | ₹2.11B | ₹620.31B |
| Enterprise Value | ₹2.42B | ₹724.61B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.06 | 1.61 |
| Enterprise to EBITDA | 13.03 | 13.32 |
| Risk & Other Metrics | ||
| Beta | -0.19 | 0.83 |
| Book Value per Share (MRQ) | ₹43.18 | ₹318.92 |
Financial Statements Comparison: Indo US Bio-Tech Ltd. vs UPL Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | INDOUS (2025) | UPLPP (2025) |
|---|---|---|
| Revenue/Sales | 1.04B | 462.62B |
| Cost of Goods Sold | 743.68M | 245.26B |
| COGS % of Revenue | 71.6% | 53.0% |
| Gross Profit | 294.70M | 217.36B |
| Gross Margin | 28.4% | 47.0% |
| Research & Development | 60.73M | 1.08B |
| Operating Income (EBIT) | 180.09M | 56.20B |
| Operating Margin | 17.3% | 12.1% |
| EBITDA | 191.24M | 74.08B |
| EBITDA Margin | 18.4% | 16.0% |
| Pre-Tax Income | 165.31M | 8.29B |
| Pre-Tax Income % of Revenue | 15.9% | 1.8% |
| Income Tax | 2.63M | 90.00M |
| Income Tax % of Revenue | 0.3% | 0.0% |
| Net Income (Profit) | 162.67M | 8.20B |
| Profit Margin | 15.7% | 1.8% |
Balance Sheet & Liquidity Metrics
| Metric | INDOUS (2025) | UPLPP (2025) |
|---|---|---|
| Cash & Equivalents | 2.48M | 94.78B |
| Total Current Assets | 867.27M | 396.61B |
| Total Current Assets % of Revenue | 83.5% | 85.7% |
| Total Current Liabilities | 163.39M | 285.69B |
| Total Current Liabilities % of Revenue | 15.7% | 61.8% |
| Long-Term Debt | 29.34M | 192.56B |
| Long-Term Debt % of Revenue | 2.8% | 41.6% |
| Total Shareholders Equity | 785.18M | 378.26B |
| Retained Earnings | 363.24M | 208.68B |
| Retained Earnings % of Revenue | 35.0% | 45.1% |
| Property, Plant & Equipment | 113,000 | 94.31B |
Cash Flow Statement Comparison
| Metric | INDOUS (2025) | UPLPP (2025) |
|---|---|---|
| Operating Cash Flow | 34.25M | 70.93B |
| Operating Cash Flow % of Revenue | 3.3% | 15.3% |
| Capital Expenditures | -8.62M | -3.73B |
| Free Cash Flow | 5.57M | 84.56B |
| FCF Margin | 0.5% | 18.3% |
| Debt Repayment | N/A | -21.37B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | INDOUS | UPLPP |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 20.05M | 844.43M |
| Float Shares | 4.68M | 563.84M |
| % Held by Insiders | 75.65% | 0.00% |
| % Held by Institutions | 0.00% | 17.49% |
| % Held by Public | 24.35% | 82.51% |
Dividend Analysis & Yield Comparison: Indo US Bio-Tech Ltd. vs UPL Ltd.
| Metric | INDOUS | UPLPP |
|---|---|---|
| Last 12-Month Dividend | ₹0.25 | ₹3.00 |
| Last 12-Month Dividend Yield | 0.16% | 0.69% |
| 3-Year Avg Annual Dividend | ₹0.08 | ₹1.00 |
| 3-Year Avg Dividend Yield | 0.09% | 0.69% |
| 3-Year Total Dividends | ₹0.25 | ₹3.00 |
| Ex-Dividend Date | Dec 03, 2024 | Jul 11, 2025 |